SEQUENCE LISTING

<110> Otsuka Pharmaceutical Co., Ltd.

<120> A method for determining the risk of drug-induced agranulocytosis

<130> OP0046

<140>
<141>

<160> 17

<170> PatentIn Ver. 2.1

<210> 1

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 1
accactgtat ttgtgacaac tc 22

<210> 2

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 2
aaatatggat cagtctcttt cc 22

<210> 3

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 3
atgttcattt tatgagggag g 21

<210> 4

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 4
aactgccaat ccagagctgc 20

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 5
tctcaccaca ccgcttcaag 20

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 6
ccacattttc ttcaagcacc 20

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 7
gagcttgctg ggatctgaac 20

<210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of

Insulin receptor substance-2 (IRS-2)

<400> 8
atgtgactcg gcgttacgca 20

<210> 9

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 9
ccttgcagtg gaagcatg 18

<210> 10

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 10
ctatcccgat tcctagatgt c 21

<210> 11

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 11
gactcatctg tgactaactc c 21

<210> 12

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 12
cctagatgtc agcttgccc 19

<210> 13

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 13
tctggaactc cagagattgc 20

<210> 14

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 14
tgctgagcgt cttcttttaa tggta 25

<210> 15

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 15
gaggcttttt tagaggaaga cc 22

<210> 16

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 16
catgtcatgg agggagcatt c 21

<210> 17

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer sequence for amplification of SNPs of Insulin receptor substance-2 (IRS-2)

<400> 17
gcaaaagtct tcctgcttcc 20